tradingkey.logo

FDA Approves Niraparib And Abiraterone Acetate Plus Prednisone For Brca2-Mutated Metastatic Castration-Sensitive Prostate Cancer

ReutersDec 12, 2025 9:23 PM

- FDA:

  • FDA: APPROVES NIRAPARIB AND ABIRATERONE ACETATE PLUS PREDNISONE FOR BRCA2-MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI